A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Part of paid clinical trials in Fort Smith, Arkansas.

Sponsor
Takeda
Study ID
NCT06973291
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

Key Dates

Start date
Jul 9, 2025
Status verified
Apr 2026
Primary completion
Apr 22, 2026
Completion
Apr 22, 2026

Study Design

Enrollment
606 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Zasocitinib or Placebo
    Participants will receive zasocitinib or matching placebo tablet, orally, once daily (QD) up to Week 16.
  • Active Comparator: Deucravacitinib or Placebo
    Participants will receive deucravacitinib 6 mg or matching placebo capsule, orally, QD up to Week 16.

Primary Outcome Measure

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16 [ Time Frame: At Week 16 ]

Locations (31)

FacilityCityStateZIPSite coordinators
Johnson DermatologyFort SmithArkansas72916-6103-
Burke Pharmaceutical ResearchHot SpringsArkansas71913-6475-
Zenith Research, Inc.Beverly HillsCalifornia90212-
First OC Dermatology Research Inc.Fountain ValleyCalifornia92708-
UNISON Clinical Trials (Shahram Jacobs md inc.)Sherman OaksCalifornia91403-
Central Connecticut Dermatology, PLLCCromwellConnecticut06416-
Yale University School of MedicineNew HavenConnecticut06511-
Direct Helpers Research CenterHialeahFlorida33012-
San Marcus Research Clinic IncMiami LakesFlorida33014-
Advanced Clinical Research InstituteTampaFlorida33607-6429-
Arlington DermatologyRolling MeadowsIllinois60008-3811-
Endeavor Health Clinical TrialsSkokieIllinois60077-
Dawes Fretzin Clinical Research Group, LLCIndianapolisIndiana46250-
Lawrence J Green, MD LLCRockvilleMaryland20850-
Henry Ford Health SystemDetroitMichigan48202-
JDR Dermatology Research, LLCLas VegasNevada89145-
Dartmouth Hitchcock Medical CenterLebanonNew Hampshire03756-
Markowitz Medical PLLC dba OptiSkin MedicalNew YorkNew York10128-
University of North Carolina at Chapel HillChapel HillNorth Carolina27516-
Bexley Dermatology Research - Probity - PPDSBexleyOhio43209-
Apex Clinical Research Center, LLC - CantonCantonOhio44718-
Apex Clinical Research Center, LLC - Mayfield HeightsMayfield HeightsOhio44124-4005-
UPMC Department of DermatologyPittsburghPennsylvania15213-3403-
Goodlettsville Dermatology ResearchGoodlettsvilleTennessee37072-
Arlington Research CenterArlingtonTexas76011-3800-
Bellaire Dermatology AssociatesBellaireTexas77401-3505-
The University of Texas Health Science Center at Houston (UTHSC-H)BellaireTexas77401-
Reveal Research InstituteDallasTexas75235-
San AntonioSan AntonioTexas78213-2250-
Texas Dermatology and Laser Specialists-San AntonioSan AntonioTexas78218-3128-
Houston Center for Clinical Research, LLCSugar LandTexas77479-1001-

Related coverage on Hipa.ai

Find similar trials in Fort Smith, AR

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Johnson Dermatology· Fort Smith, ARBurke Pharmaceutical Research· Hot Springs, ARZenith Research, Inc.· Beverly Hills, CAFirst OC Dermatology Research Inc.· Fountain Valley, CAUNISON Clinical Trials (Shahram Jacobs md inc.)· Sherman Oaks, CACentral Connecticut Dermatology, PLLC· Cromwell, CT

Related Studies